Clinical Trial Search

Primary: Percentage of Dose-limiting Toxicities — 0; 0; 17 Percentage of dose-limiting toxicities

Primary: Tumor Response — 0; 0 participants

Primary: Safety: Toxicity Symptoms Graded According to CTCAE v4.03. — 61; 139; 411; 7 Number of Events

Primary: Objective Response Rate — 4; 7; 13; 32 Participants

Primary: Dose Limiting Toxicity — 0; 0 participants with DLTs

Primary: Number of Phase I Participants With Dose-Limiting Toxicity Events (Phase I) Maximum Tolerated Dose (MTD) (Phase I) as Measured by the Number of Participants With Dose…

Primary: Number of Participants With Any (Serious and Non-Serious) Adverse Event Measured to Assess Safety and Tolerability. — 12 participants

Primary: Phase I: Maximum Tolerated Dose (MTD) / Recommended Phase II Dose (RP2D) — 100 million plaque forming units per mL

Primary: Number of Participants With Objective Radiographic Response — 5; 2 Participants

Primary: The Effectiveness of MV-NIS Therapy as Measured by the International Myeloma Working Group (IMWG) Guidelines

Primary: Tolerability Evaluated by NCI CTCAE v5.0 — 52; 130; 6; 11 Number of Events

Primary: Progression-free Survival (PFS) — 3.94; 4.39 Months

Primary: Determine Radiographic Response Rate of Patients Enrolled in the Phase 2a Portion of the Study — 0; 0; 0; 1 Participants

Primary: Number of Participants With Grade 1-5 Adverse Events — 4; 12; 4; 13 Participants

Primary: Progression-free Survival Using RECIST v. 1.1 — 4.9; 5.2 months

Primary: Number of Participants With Treatment Related Adverse Events — 21 Participants

Primary: Freedom From Biochemical/Clinical Failure (FFF) — 20; 21 participants

Primary: Dose Limiting Toxicity (DLT) — 0; 0; 0 Participants

Primary: Number of Participants With Side Effects After Ad/PNP-F-araAMP Treatment — 12; 8; 8; 5 participants

Primary: 12 Month Progression-free Survival (PFS-12) — 215; 69 Days — p=0.927

Primary: Number of Participants With Immediate and Short Term Toxicity of Infusion Over 8 Weeks — 0; 0; 3 Participants

Primary: Number of Participants Experiencing Clinically Significant Infections or Episodes of End-organ Disease — 3 Participants

Primary: Incidence of Adverse Events and Dose Limiting Adverse Events — 0; 69; 47; 44 percentage of participants

Primary: Change in IL-2 Levels — 1.8; 4.0; 7.9; 2.1 pg/100 gm protein — p=<0.05

Primary: Comparison of Overall Survival (OS) Between the Active Treatment Group (Arms 1 and 2) and the Control Group (Arm 3) — 16.9; 16.2; 20.6 months — p=0.196

Primary: Recurrence-free Survival at 2 Years — 13; 10 participants

Primary: Number of Patients Where a Suitable VST Line Could be Found — 80 Participants

Primary: Number of Participants With Reported Adverse Events by Type — 3; 3; 1; 1 Participants

Primary: Proportion of Subjects Achieving Disease Control (Non-progressive Disease) at 8 Weeks After Initiation of Treatment — 0.7273; 0.6429 Proportion of evaluable participants

Primary: Number of Treatment Related Adverse Events — 0; 0; 0; 0 adverse events